Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 12
Submit an article Journal homepage
1,068
Views
14
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus

Georg HessDepartment of Hematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg University, Mainz, Germany; Correspondence[email protected]
View further author information
,
Simon RuleDerriford Hospital, Plymouth University Medical School, Plymouth, UK; View further author information
,
Wojciech JurczakDepartment of Hematology, Jagiellonian University, Krakow, Poland; View further author information
,
Mats JerkemanSkånes University Hospital, Lund University, Lund, Sweden; View further author information
,
Rodrigo Santucci SilvaInstituto de Ensino e Pesquisa Sao Lucas, Sao Paulo, Brazil; View further author information
,
Chiara RusconiDivision of Hematology, Department of Hematology and Oncology, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy; View further author information
,
Dolores CaballeroInstituto Biosanitario de Salamanca, Hospital Clinico Universitario Salamanca, Salamanca, Spain; View further author information
,
Cristina JoaoInstitutto Português de Oncologia de Lisboa, Portugal and Champalimaud Centre for the Unknown, Hematology, Lisbon, Portugal; ORCID Iconhttp://orcid.org/0000-0002-3978-766XView further author information
ORCID Icon,
Mathias Witzens-HarigKlinikum der Ruprechts-Karls-Universität Heidelberg – Med. Klinik u. Poliklinik V, Heidelberg, Germany; View further author information
,
Isabelle Bence-BrucklerThe Ottawa Hospital, General Campus, Ottawa, ON, Canada; View further author information
,
Seok-Goo ChoSeoul St. Mary’s Hospital, Seocho-gu, Seoul, South Korea; View further author information
,
Wenjiong ZhouJanssen Research & Development, Raritan, NJ, USA; View further author information
,
Jenna D. GoldbergJanssen Research & Development, Raritan, NJ, USA; View further author information
,
Cristina TrambitasJanssen Inc, Ontario, Canada; View further author information
,
Christopher EnnyJanssen Research & Development, Raritan, NJ, USA; View further author information
,
Jessica VermeulenJanssen Research & Development, LLC, Leiden, The Netherlands; View further author information
,
Shana TrainaJanssen Research & Development, Raritan, NJ, USA; View further author information
,
Chiun-Fang ChiouJanssen Research & Development, Raritan, NJ, USA; View further author information
,
Joris DielsJanssen Pharmaceuticals, Beerse, Belgium; View further author information
&
Martin DreylingDepartment of Medicine III, Klinikum der Universität München, LMU, Munich, GermanyView further author information
 show all
Pages 2824-2832 | Received 14 Mar 2017, Accepted 27 Apr 2017, Published online: 30 May 2017

References

  • Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009;27:511–518.
  • Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367:520–531.
  • Shah N, Hutchinson C, Rule S. Ibrutinib for the treatment of mantle cell lymphoma. Expert Rev Hematol. 2014;7:521–531.
  • Wang M, Goy A, Martin P, et al. Efficacy and safety of single-agent ibrutinib in patients with mantle cell lymphoma who progressed after bortezomib therapy. Lymphoma. 2014;124:4471.
  • Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–516.
  • Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126:739–745.
  • Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27:3822–3829.
  • Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387:770–778.
  • Hlubocky FJ, Webster K, Cashy J, et al. The development and validation of a measure of health-related quality of life for non-Hodgkin's lymphoma: the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym). Lymphoma. 2013;2013:147176.
  • Eremenco S, Webster K, Kubkova L, et al. Development and multilingual validation of the FACT-Lymphoma instrument. Qual Life Res. 2004;13:1501.
  • EuroQol Group. EuroQol – a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208.
  • Cella D, Jensen SE, Webster K, et al. Measuring health-related quality of life in leukemia: the Functional Assessment of Cancer Therapy–Leukemia (FACT-Leu) questionnaire. Value Health. 2012;15:1051–1058.
  • EuroQol Group [Internet] van Reenen M, Janssen B. EQ-5D-5L User Guide, version 2.1. Available from: http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Folders_Flyers/EQ-5D-5L_UserGuide_2015.pdf
  • Yost KJ, Thompson CA, Eton DT, et al. The Functional Assessment of Cancer Therapy – General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma. Leuk Lymphoma. 2013;54:290–297.
  • Perry S, Kowalski TL, Chang CH. Quality of life assessment in women with breast cancer: benefits, acceptability and utilization. Health Qual Life Outcomes. 2007;5:24.
  • Carter GC, Liepa A, Zimmerman AH, et al. Validation of the Functional Assessment of Therapy-Lymphoma (FACT-LYM) in patients with relapsed/refractory mantle cell lymphoma. Paper Presented at: 50th Annual meeting of the American Society of Hematology (ASH); December 6–9, 2008; San Francisco, CA.
  • Cella D, Webster K, Cashy J, Development of a measure of health-related quality of life for non-Hodgkin’s lymphoma clinical research: the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym). Paper Presented at: American Society of Hematology (ASH); November 2005; Atlanta, GA. Abstract 750.
  • Harrison CN, Mesa RA, Kiladjian JJ, et al. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. Br J Haematol. 2013;162:229–239.
  • Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5:70.
  • Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558–565.
  • Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–655.
  • Kluetz PG, Slagle A, Papadopoulos EJ, et al. Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms. Clin Cancer Res. 2016;22:1553–1558.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.